For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Bioventus Inc (NASDAQ: BVS) closed at $7.38 in the last session, down -1.99% from day before closing price of $7.53. In other words, the price has decreased by -$1.99 from its previous closing price. On the day, 0.2 million shares were traded. BVS stock price reached its highest trading level at $7.5358 during the session, while it also had its lowest trading level at $7.33.
Ratios:
We take a closer look at BVS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.42. For the most recent quarter (mrq), Quick Ratio is recorded 1.14 and its Current Ratio is at 1.74. In the meantime, Its Debt-to-Equity ratio is 2.05 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on July 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $12.
On December 17, 2024, JP Morgan Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $12 to $13.
Canaccord Genuity Upgraded its Hold to Buy on December 07, 2023, while the target price for the stock was maintained at $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when NOHRA GUY P sold 10,000 shares for $7.57 per share. The transaction valued at 75,658 led to the insider holds 116,610 shares of the business.
NOHRA GUY P bought 10,000 shares of BVS for $75,658 on Dec 04 ’25. On Nov 07 ’25, another insider, McMurry-Heath Michelle, who serves as the Director of the company, sold 17,701 shares for $7.42 each. As a result, the insider received 131,255 and left with 56,997 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BVS now has a Market Capitalization of 494286400 and an Enterprise Value of 834448384. As of this moment, Bioventus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 65.72, and their Forward P/E ratio for the next fiscal year is 10.40. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.08 while its Price-to-Book (P/B) ratio in mrq is 2.98. Its current Enterprise Value per Revenue stands at 1.48 whereas that against EBITDA is 12.65.
Stock Price History:
The Beta on a monthly basis for BVS is 0.79, which has changed by -0.31545454 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, BVS has reached a high of $11.25, while it has fallen to a 52-week low of $5.81. The 50-Day Moving Average of the stock is 1.61%, while the 200-Day Moving Average is calculated to be 1.97%.
Shares Statistics:
According to the various share statistics, BVS traded on average about 306.69K shares per day over the past 3-months and 297950 shares per day over the past 10 days. A total of 66.97M shares are outstanding, with a floating share count of 46.05M. Insiders hold about 31.24% of the company’s shares, while institutions hold 54.17% stake in the company. Shares short for BVS as of 1764288000 were 1806746 with a Short Ratio of 5.79, compared to 1761868800 on 1920915. Therefore, it implies a Short% of Shares Outstanding of 1806746 and a Short% of Float of 6.959999999999999.
